124 related articles for article (PubMed ID: 22182739)
1. [FDG-PET and endometrial cancer].
Kolesnikov-Gauthier H; Carpentier P
Bull Cancer; 2012 Jan; 99(1):21-8. PubMed ID: 22182739
[TBL] [Abstract][Full Text] [Related]
2. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer.
Kitajima K; Murakami K; Yamasaki E; Hagiwara S; Fukasawa I; Inaba N; Kaji Y; Sugimura K
Ann Nucl Med; 2008 Feb; 22(2):103-9. PubMed ID: 18311534
[TBL] [Abstract][Full Text] [Related]
3. Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases.
Signorelli M; Guerra L; Buda A; Picchio M; Mangili G; Dell'Anna T; Sironi S; Messa C
Gynecol Oncol; 2009 Nov; 115(2):231-5. PubMed ID: 19695685
[TBL] [Abstract][Full Text] [Related]
4. ¹⁸F-Fluorodeoxyglucose uptake and clinicopathological features of recurrent or metastatic endometrial stromal sarcoma.
Inoue K; Tsubamoto H; Kawata S; Hao H; Ikeda Y; Oku N; Hirota S
J Obstet Gynaecol Res; 2014 Feb; 40(2):576-82. PubMed ID: 24118160
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature.
Kakhki VR; Shahriari S; Treglia G; Hasanzadeh M; Zakavi SR; Yousefi Z; Kadkhodayan S; Sadeghi R
Int J Gynecol Cancer; 2013 Nov; 23(9):1536-43. PubMed ID: 24172090
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography in gynecological malignancies.
Kumar R; Chauhan A; Jana S; Dadparvar S
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1033-44. PubMed ID: 16831075
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of (18)F-2-deoxy-fluoro-D-glucose positron emission tomography for pN2 lymph nodes in patients with lung cancer.
Ozawa Y; Hara M; Sakurai K; Nakagawa M; Tamaki T; Nishio M; Shibamoto Y
Acta Radiol; 2010 Mar; 51(2):150-5. PubMed ID: 20092375
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer.
Horowitz NS; Dehdashti F; Herzog TJ; Rader JS; Powell MA; Gibb RK; Grigsby PW; Siegel BA; Mutch DG
Gynecol Oncol; 2004 Dec; 95(3):546-51. PubMed ID: 15581961
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of the diagnostic value of (18)F-FDG PET-CT and enhanced CT for staging of lymph node metastasis in non-small cell lung cancer].
Yang WF; Tan GZ; Fu Z; Yu JM
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):925-8. PubMed ID: 20193335
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
[TBL] [Abstract][Full Text] [Related]
11. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.
Nakajima N; Kataoka M; Sugawara Y; Ochi T; Kiyoto S; Ohsumi S; Mochizuki T
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):738-46. PubMed ID: 24064322
[TBL] [Abstract][Full Text] [Related]
12. Flare phenomenon in positron emission tomography in a case of breast cancer--a pitfall of positron emission tomography imaging interpretation.
Tu DG; Yao WJ; Chang TW; Chiu NT; Chen YH
Clin Imaging; 2009; 33(6):468-70. PubMed ID: 19857808
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET staging of head and neck cancer--can improved imaging lead to improved treatment?
Schwartz DL; Macapinlac HA; Weber RS
J Natl Cancer Inst; 2008 May; 100(10):688-9. PubMed ID: 18477798
[No Abstract] [Full Text] [Related]
14. Detection of recurrence by 18F-FDG PET in patients with endometrial cancer showing no evidence of disease.
Ryu SY; Kim K; Kim Y; Park SI; Kim BJ; Kim MH; Choi SC; Lee ED; Lee KH; Kim BI
J Korean Med Sci; 2010 Jul; 25(7):1029-33. PubMed ID: 20592894
[TBL] [Abstract][Full Text] [Related]
15. Correlation between expression of biological markers and [F]fluorodeoxyglucose uptake in endometrial cancer.
Jo MS; Choi OH; Suh DS; Yun MS; Kim SJ; Kim GH; Jeon HN
Oncol Res Treat; 2014; 37(1-2):30-4. PubMed ID: 24613906
[TBL] [Abstract][Full Text] [Related]
16. Current and future use of positron emission tomography (PET) in breast cancer.
Mankoff DA; Eubank WB
J Mammary Gland Biol Neoplasia; 2006 Apr; 11(2):125-36. PubMed ID: 17075687
[TBL] [Abstract][Full Text] [Related]
17. Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT.
Crivellaro C; Signorelli M; Guerra L; De Ponti E; Pirovano C; Fruscio R; Elisei F; Montanelli L; Buda A; Messa C
Gynecol Oncol; 2013 Aug; 130(2):306-11. PubMed ID: 23707673
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
[TBL] [Abstract][Full Text] [Related]
20. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
